

Erratum to “Recommendations on phenylketonuria in Turkey” [Turk J Pediatr 2022; 64: 413-434]

Turgay Coşkun¹, Mahmut Çoker², Neslihan Önenli Mungan³,
Hülya Gökmen Özel⁴, H. Serap Sivri¹

¹Division of Pediatric Metabolism and Nutrition, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara; ²Division of Pediatric Metabolism and Nutrition, Department of Pediatrics, Ege University Faculty of Medicine, İzmir; ³Division of Pediatric Metabolism and Nutrition, Department of Pediatrics, Çukurova University Faculty of Medicine, Adana; ⁴Department of Nutrition and Dietetics, Hacettepe University Faculty of Health Sciences, Ankara, Türkiye.

After publication of the article the authors wished to clarify the safety profile of pegvaliase. In Statement #12, the sentence “Current information about PegPAL indicates that it is too early to be used in pediatric patients, and there are many issues to be resolved before it is accepted as a safe and reliable treatment option.” is now replaced by “In Europe, pegvaliase (rAvPAL-PEG) is indicated for the treatment of patients with phenylketonuria aged 16 years or older who have inadequate blood phenylalanine control (>600 µmol/L) despite prior management with the available treatment options. Studies on children younger than 16 years are ongoing. At the time of writing, clinical experience on the use of pegvaliase in Turkey is lacking.” The authors would like to apologize for this and any inconvenience it may have caused.

DOI of original article: <https://doi.org/10.24953/turkjped.2021.4098>

✉ Turgay Coşkun
drturgaycoskun@gmail.com